If you only skimmed the Medicare reimbursement headaches and net losses around AVITA Medical at the start of 2026, this outcome would be hard to guess. Holding AVITA Medical from the start of the year would have returned 347.0%, including dividends. Revenue and net margin both improved by Q2 2026, yet the swing in shareholder wealth far outpaced those accounting gains. If you had known only what was on record in early January, how would you have weighed that risk against this payoff?
Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.
If the move has made AVITA Medical harder to judge, start where the gap is still open and scan 28 high quality undervalued stocks .
The Two AVITA Medical Stories Investors Had To Weigh
The shares cost US$3.45 at the start of the period, and AVITA Medical split opinion into two very different but reasonable stories.
On the bullish side, the Fair Value was US$8.26, described as 139% above the start price. Believers leaned on an assumed 42.5% revenue growth rate and a future profit margin of 35.8%, supported by expectations that Medicare reimbursement clarity and trauma expansion would rebuild provider confidence.
The bearish view pinned Fair Value at US$3, or 13% below the start price. That camp worked off a 21.2% revenue growth assumption and a 16.3% profit margin, while highlighting ongoing reimbursement pressure, reliance on RECELL and regulatory delays as key risks that could strain profitability and expansion.
What The Results Changed For AVITA Medical
AVITA Medical reported Q2 2026 revenue of US$21.702m against US$18.418m a year earlier, and the quarterly loss narrowed from US$9.92m to US$7.663m. Net margin improved from a loss of 53.9% to a loss of 35.3%. The higher sales and less severe loss supported the bullish growth story, yet ongoing losses kept the profitability promise unproven.
The lesson is simple. When a thesis leans on future margins, track the reported net margin each period and test whether losses are actually shrinking toward the target level.
What AVITA Medical's Repricing Already Assumes
AVITA Medical now trades at US$15.51, far above the start price and above where the selected Narrative's Fair Value currently sits. That view links the recent surge to improving execution, broader RECELL and PermeaDerm uptake, and tighter costs, while still treating the stock as ahead of its own central case.
A buyer today is effectively betting that wider hospital adoption, new products and cost controls will support durable growth and future profitability. The selected Narrative asks how that assumption holds up if reimbursement frictions, product concentration and slower international rollout keep pressuring liquidity and long run earnings quality.
"Continued reimbursement issues, product concentration, margin pressure, liquidity challenges, and slow international expansion collectively threaten AVITA's revenue growth, profitability, and overall financial stability."
The price and this Narrative do not agree. → Uncover what this Narrative says AVITA Medical is actually worth
Looking Beyond AVITA Medical
AVITA Medical asks you to judge a focused burn care story. You could instead consider a broader healthcare group tackling several complex conditions.
Hospitals that use AVITA's products still rely on other treatments for cancer, immune conditions and neurological disorders. One major pharmaceutical and device company concentrates on those needs.
It advances new drugs through late stage trials and regulatory review. The same business refines surgical tools and eye procedures to keep specialists engaged.
Those choices create a very different risk mix compared with AVITA Medical. That broader footing might reshape expectations for resilience when individual products face pressure.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 21% above its price
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include RCEL .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
